Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

NCT03616470 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

388

Enrollment

INDUSTRY

Sponsor class

Stopped Trial failed to meet primary endpoint.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Uproleselan
DRUG: Placebo

Sponsor

GlycoMimetics Incorporated